| Literature DB >> 19287096 |
Steven D Crowley1, Matthew P Vasievich, Phillip Ruiz, Samantha K Gould, Kelly K Parsons, A Kathy Pazmino, Carie Facemire, Benny J Chen, Hyung-Suk Kim, Trinh T Tran, David S Pisetsky, Laura Barisoni, Minolfa C Prieto-Carrasquero, Marie Jeansson, Mary H Foster, Thomas M Coffman.
Abstract
Studies in humans and animal models indicate a key contribution of angiotensin II to the pathogenesis of glomerular diseases. To examine the role of type 1 angiotensin (AT1) receptors in glomerular inflammation associated with autoimmune disease, we generated MRL-Faslpr/lpr (lpr) mice lacking the major murine type 1 angiotensin receptor (AT1A); lpr mice develop a generalized autoimmune disease with glomerulonephritis that resembles SLE. Surprisingly, AT1A deficiency was not protective against disease but instead substantially accelerated mortality, proteinuria, and kidney pathology. Increased disease severity was not a direct effect of immune cells, since transplantation of AT1A-deficient bone marrow did not affect survival. Moreover, autoimmune injury in extrarenal tissues, including skin, heart, and joints, was unaffected by AT1A deficiency. In murine systems, there is a second type 1 angiotensin receptor isoform, AT1B, and its expression is especially prominent in the renal glomerulus within podocytes. Further, expression of renin was enhanced in kidneys of AT1A-deficient lpr mice, and they showed evidence of exaggerated AT1B receptor activation, including substantially increased podocyte injury and expression of inflammatory mediators. Administration of losartan, which blocks all type 1 angiotensin receptors, reduced markers of kidney disease, including proteinuria, glomerular pathology, and cytokine mRNA expression. Since AT1A-deficient lpr mice had low blood pressure, these findings suggest that activation of type 1 angiotensin receptors in the glomerulus is sufficient to accelerate renal injury and inflammation in the absence of hypertension.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19287096 PMCID: PMC2662542 DOI: 10.1172/JCI34862
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808